Dr. Nagi El-Saghir reviews major SABCS 2025 advances in adjuvant endocrine therapy for HR-positive breast cancer, highlighting the oral SERD jeridistran, which improved invasive disease-free survival compared with standard therapy, and discussing how it may integrate with CDK4/6 inhibitors in high-risk patients.
